Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
2019: 10 Deals That Shook up the Diagnostics Industry
Bio-Techne Corporation (NASDAQ:TECH)*, formerly, Techne Corp

Organization & Developments: Bio-Techne

Parents

*Bio-Tech derives 65% of its revenue from proteins, antibodies and reagents, and the rest comes from sales of instruments and diagnostic equipment used by larger players in biotech
*BioTechne made moves in the liquid biopsy space when it revealed it would acquire Exosome Diagnostics for $250 million plus $325 million in potential milestones.
*Makes medical testing and diagnostic products
2022: Bio-Techne: Recent Weakness, Charts Suggest It's Now A Buy (Technical Analysis)_ seekingalpha.com
2023: Bio-Techne Corporation: Long-Term Quality, But At A Price
2023: Bio-Techne: Quality Play Struggles But Looks More Compelling_ seekingalpha.com
2024: Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
2025: Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain